|
Sign In to gain access to subscriptions and/or personal tools.
|
Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases
S A Chambers
Centre for Rheumatology, The Middlesex Hospital, University College, London, UK
D Isenberg
Centre for Rheumatology, The Middlesex Hospital, University College, London, UK, D.Isenberg{at}ucl.ac.uk
The use of B cell depletion as a mode of treatment for non-Hodgkin’s lymphoma was first utilized in 1997 when Rituximab, a chimeric human-mouse monoclonal antibody which has a high affinity to the CD20 antigen expressed on B cells, became available. Over 500 000 lymphoma patients have been treated worldwide with this drug and it has a good safety record. The notion that B cells might be critical to the development of rheumatoid arthritis led to the extension of the use of B cell depletion to this condition and a recent double blind controlled trial has shown very encouraging results. In addition, B cell depletion either using Rituximab alone, or in combination with cyclophosphamide and corticosteroids has also been reported to have been of great benefit in some patients with severe systemic lupus erythematosus albeit in open label studies. This review considers the mechanism of action of the drug, the clinical trials that have been reported, and tries to place its current use in patients with autoimmune rheumatic disease in context.
Key Words: B cell depletion • CD20 • rheumatoid arthritis • Rituximab • systemic lupus erythematosus
Lupus, Vol. 14, No. 3,
210-214 (2005)
DOI: 10.1191/0961203305lu2138oa
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Tew, N. Rabbee, K. Wolslegel, H-J. Hsieh, J. Monroe, T. Behrens, P. Brunetta, and M. Keir
Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus
Lupus,
February 1, 2010;
19(2):
146 - 157.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, J. P. Leonard, L. Fayad, B. Coiffier, M.-O. Petillon, M. Coleman, S. J. Schuster, M. J.S. Dyer, H. Horne, N. Teoh, et al.
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
J. Clin. Oncol.,
July 10, 2009;
27(20):
3346 - 3353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C B Driver, M Ishimori, and M H Weisman
The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
Ann Rheum Dis,
October 1, 2008;
67(10):
1374 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rahman and D. A. Isenberg
Systemic Lupus Erythematosus
N. Engl. J. Med.,
February 28, 2008;
358(9):
929 - 939.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cianchini, R. Corona, A. Frezzolini, M. Ruffelli, B. Didona, and P. Puddu
Treatment of Severe Pemphigus With Rituximab: Report of 12 Cases and a Review of the Literature
Arch Dermatol,
August 1, 2007;
143(8):
1033 - 1038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
CA Cancer J Clin,
July 1, 2006;
56(4):
226 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ruggenenti, C. Chiurchiu, M. Abbate, A. Perna, P. Cravedi, M. Bontempelli, and G. Remuzzi
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
Clin. J. Am. Soc. Nephrol.,
July 1, 2006;
1(4):
738 - 748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M Stachnik
Rituximab in the Treatment of Acquired Hemophilia
Ann. Pharmacother.,
June 1, 2006;
40(6):
1151 - 1157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
